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The in vitro activity of trovafloxacin (CP-99,219), a new fluoroquinolone, was compared with the in vitro
activities of other commonly used quinolones and other antimicrobial agents against 445 gram-positive
microorganisms isolated between 1986 and 1995 from patients with endocarditis and those with other blood-
stream infections. The MICs at which 90% of the isolates are inhibited (MIC90) of trovafloxacin for methicillin-
susceptible staphylococci, viridans group streptococci, and enterococci were 0.06, 0.25, and 0.5 mg/liter,
respectively. The MIC90 of trovafloxacin for vancomycin-resistant enterococci as well as for methicillin-
resistant Staphylococcus aureus and methicillin-susceptible and ciprofloxacin-resistant S. aureus, isolated from
sources other than blood, was 1 mg/liter. For the quinolones the rank order of activity was trovafloxacin >
sparfloxacin > ciprofloxacin 5 ofloxacin > pefloxacin. Depending on the species tested, trovafloxacin was 4-
to 64-fold more active than ciprofloxacin. Further experimental and in vivo studies are warranted to evaluate
the efficacy of trovafloxacin in the treatment of bacterial endocarditis and other infections caused by gram-
positive organisms.
Quinolones represent a major class of antimicrobial agents
and are derivatives of nalidixic acid, which was introduced in
the 1960s. The fluoroquinolones, introduced in the late 1970s,
are synthetically developed agents which are used worldwide to
treat a wide range of infections (22). Ciprofloxacin, ofloxacin,
and pefloxacin are examples of these very potent compounds,
which have markedly improved activities compared to earlier
quinolones (29). Although they are highly active against gram-
negative microorganisms, failures in the treatment of serious
infections caused by gram-positive organisms have been en-
countered (13, 14, 26). Further developments have produced
newly synthesized agents, like sparfloxacin and temafloxacin,
with improved activities against staphylococci and streptococci
(1, 5). The structure-activity relationship for the quinolone
agents has recently been reviewed (9). The substitution of an
alkylated pyrrolidine at the 7 position of the molecule greatly
enhances activity against gram-positive microorganisms.
Trovafloxacin (CP-99,219) is such a newly developed com-
pound (11).
The objective of this study was to compare the in vitro
activities of trovafloxacin and other relevant antimicrobial
agents against gram-positive isolates from patients with endo-
carditis and those with other bloodstream infections.
A total of 445 gram-positive microorganisms isolated from
blood were tested in this study. Of these, 355 strains were
isolated between 1986 and 1988 from patients with endocardi-
tis in The Netherlands (27). Another 90 viridans group strep-
tococci were isolated between 1990 and 1995 from hospitalized
patients with endocarditis or other bloodstream infections at
the University Hospital of Rotterdam. In addition, we tested
20 vancomycin-resistant enterococci (VRE) harboring the
vanA gene, 13 methicillin-resistant Staphylococcus aureus
(MRSA) organisms harboring the mecA gene, 13 ciprofloxa-
cin-resistant but methicillin-susceptible S. aureus (MSSA) or-
ganisms, and 19 ciprofloxacin-resistant and coagulase-negative
staphylococci (CoNS). These strains were isolated from
sources other than blood. All MRSA organisms and VRE were
unique and epidemiologically unrelated strains. All staphylo-
cocci (n 5 123) and b-hemolytic streptococci (n 5 11) were
identified by standard methods as described previously (21,
25). All viridans group streptococci (n 5 276) and enterococci
(n 5 35) were identified with the API 32 rapid system by
following the instructions of the manufacturer (Biomerieux,
Marcy l’Etoile, France). The strains belonged to the following
species or groups: MSSA (n 5 87), CoNS (n 5 36), Entero-
coccus faecalis (n 5 35), b-hemolytic streptococci (n 5 11),
Streptococcus oralis (n 5 62), Streptococcus mitis (n 5 56),
“Streptococcus milleri” (n 5 25), Streptococcus gordonii (n 5
23), Streptococcus bovis (n 5 20), Streptococcus mutans (n 5
18), and other viridans group streptococci (n 5 72). The fol-
lowing antibiotics were tested: trovafloxacin (Pfizer bv, Capelle
aan de IJssel, The Netherlands [NL]), sparfloxacin and pe-
floxacin (Rhone-Poulenc-Rorer, Amstelveen, NL), ciprofloxa-
cin (Bayer bv, Mijdrecht, NL), ofloxacin (Hoechst Roussel bv,
Hoevelaken, NL), vancomycin (Eli-Lilly, Nieuwegein, NL),
teicoplanin and penicillin (Yamanouchi Pharma, Leiderdorp,
NL), and amoxicillin and flucloxacillin (SmithKline Beecham,
Rijswijk, NL). All in vitro experiments were performed by the
agar dilution method according to the recommendations of the
National Committee for Clinical Laboratory Standards (23).
The following media were used: for staphylococci and entero-
cocci, Mueller-Hinton medium (Difco, Amsterdam, NL); and
for b-hemolytic streptococci and viridans group streptococci,
Mueller-Hinton medium supplemented with 5% sheep blood.
The final inoculum was approximately 104 CFU per spot. S.
aureus ATCC 29213, E. faecalis ATCC 29212, and Streptococ-
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cus pneumoniae ATCC 40619 were used as control strains. All
media were incubated for 18 h in 5% CO2. The MIC was
defined as the lowest concentration of the drug that prevented
visible growth.
The in vitro activities of trovafloxacin, four other fluoro-
quinolones, and four other relevant antimicrobial agents
against 455 isolates from patients with endocarditis or other
bloodstream infections are shown in Tables 1 and 2.
The MICs at which 90% of the isolates are inhibited
(MIC90) of trovafloxacin for the staphylococcal isolates (MSSA
and CoNS) were #0.06 mg/liter (Table 1). The MIC90 of spar-
floxacin for staphylococci was 1 twofold dilution higher than
that of trovafloxacin. The MICs of ciprofloxacin and ofloxacin
were 8- to 16-fold higher than the MICs of trovafloxacin. How-
ever, this group of organisms, isolated from patients with en-
docarditis and those with other bloodstream infections, con-
tained no MRSA organisms and only two ciprofloxacin-
resistant S. aureus organisms, reflecting the low prevalence of
these resistant organisms in The Netherlands. Therefore, 13
MRSA organisms isolated from sources other than blood were
collected and tested. Trovafloxacin was 8- to 64-fold more
active than ciprofloxacin against these MRSA organisms and
inhibited 90% of the strains at 1 mg/liter, in contrast to the
MIC90 of trovafloxacin for the methicillin-susceptible isolates
of #0.06 mg/liter (Tables 1 and 3). The in vitro activity of
trovafloxacin against MRSA has previously been evaluated by
others (15, 20). In those studies, the MIC90 of trovafloxacin for
ciprofloxacin-resistant and -susceptible MRSA varied from
,0.125 to 128 mg/liter (MIC50, 8 mg/liter) and 0.03 to 0.125
mg/liter (MIC50, 0.062 mg/liter), respectively, 8- to 64-fold
lower than the MIC90 of ciprofloxacin. It is important to note
that those studies did not include ciprofloxacin-resistant
MSSA. We report here that 90% of the ciprofloxacin-resistant
MSSA were inhibited by a MIC of trovafloxacin of 1 mg/liter,
32-fold lower than that of ciprofloxacin (Table 3).
The frequency at which spontaneous mutations arise, result-
ing in resistance to trovafloxacin, has been studied for S. aureus
and S. pneumoniae (2, 16). Exposure of S. aureus to a concen-
tration of trovafloxacin of 0.12 mg/liter failed to select resistant
mutants (2). However, at trovafloxacin concentrations of $0.5
mg/liter, resistant mutants of S. pneumoniae arose at a fre-
quency of #9.1 3 1029 (16). At comparable factors above the
MICs of ciprofloxacin and trovafloxacin, the frequencies of
mutation in S. pneumoniae appeared to be similar for the two
fluoroquinolones (16). Furthermore, mutants resistant to cip-
rofloxacin or trovafloxacin at concentrations of $10 times the
MIC could not be obtained (16). In view of its anticipated
tissue concentrations and its greater in vitro activity against S.
aureus and S. pneumoniae, trovafloxacin might be less likely
than ciprofloxacin to select resistance in these microorganisms
in vivo (2). Therefore, on the basis of these in vitro studies,
trovafloxacin appears to be an interesting drug for the treat-
ment of infection with ciprofloxacin-susceptible MRSA. Al-
though trovafloxacin is clearly more active against ciprofloxa-
cin-resistant staphylococci than ciprofloxacin, it may not show
sufficient activity against all ciprofloxacin-resistant staphylo-
cocci to warrant its clinical use in the treatment of infections
with this resistant organism.
Ninety percent of the enterococci were inhibited by 0.5 mg
of trovafloxacin per liter, 1 mg of sparfloxacin per liter, and 2
mg of ciprofloxacin per liter. The activities against 20 VRE
from sources other than blood are presented in Table 3. Ninety
percent of those were inhibited by 1 mg of trovafloxacin per
liter and 4 mg of ciprofloxacin per liter. A breakpoint of 2
mg/liter for susceptibility to trovafloxacin has recently been
proposed (7). The MICs for all VRE were #2 mg/liter, in
contrast to the study by Cormican and Jones (7), which com-
prised 150 VRE and reported only 37% of these VRE to be
susceptible to 2 mg of trovafloxacin per liter. However, our
data are more in concordance with those of Coque et al., who
reported 80% of VRE to be susceptible to 2 mg of trovafloxa-
cin per liter (6). In summary, trovafloxacin shows increased
activity compared to that of ciprofloxacin against most vanco-
mycin-susceptible enterococci and some VRE and, therefore,
might be considered for the treatment of enterococcal infec-
tions.
The MIC90 of trovafloxacin and sparfloxacin for the viridans
group streptococci were 0.25 and 1 mg/liter, respectively. The
MIC90 of ofloxacin and ciprofloxacin for these organisms, how-
TABLE 1. In vitro activities of trovafloxacin (CP-99,219) and other
agents against 455 gram-positive organisms from patients with
endocarditis and those with other bloodstream infections
Microorganism
(no. of strains) Antibiotic
MIC (mg/liter)
Range 50% 90%
MSSA (87) Trovafloxacin 0.015–1 0.03 0.06
Sparfloxacin 0.015–8 0.06 0.125
Ciprofloxacin 0.125–128 0.5 1
Ofloxacin 0.125–16 0.25 0.5
Pefloxacin 0.25–64 0.5 1
Penicillin 0.03–.2 .2 .2
Flucloxacillin 0.125–1 0.25 0.5
Vancomycin 0.5–2 1 1
Teicoplanin 0.5–2 1 2
CoNS (36) Trovafloxacin ,0.008–0.125 0.06 0.06
Sparfloxacin 0.03–0.5 0.06 0.125
Ciprofloxacin ,0.015–2 0.25 0.5
Ofloxacin ,0.008–1 0.5 0.5
Pefloxacin 0.25–2 0.5 1
Penicillin 0.03–.2 0.5 .2
Flucloxacillin 0.06–8 0.25 2
Vancomycin 0.5–4 2 2
Teicoplanin ,0.125–16 1 4
E. faecalis (35) Trovafloxacin 0.015–0.5 0.25 0.5
Sparfloxacin 0.06–1 0.5 1
Ciprofloxacin 0.25–4 1 2
Ofloxacin 0.25–16 4 8
Pefloxacin 0.125–8 4 8
Amoxicillin ,0.06–32 0.5 4
Vancomycin 1–8 1 4
Teicoplanin 0.125–1 0.5 1
Viridans group
streptococci (276)
Trovafloxacin ,0.008–.128 0.125 0.25
Sparfloxacin 0.03–32 0.5 1
Ciprofloxacin 0.125–64 2 8
Ofloxacin ,0.008–32 2 4
Pefloxacin 0.015–.128 16 64
Penicillin 0.008–16 0.06 0.5
Amoxicillin 0.008–.16 0.06 0.5
Vancomycin 0.06–8 1 2
Teicoplanin ,0.015–16 0.25 0.25
b-Hemolytic
streptococci (11)
Trovafloxacin 0.125–0.25 0.125 0.25
Sparfloxacin 0.25–0.5 0.5 0.5
Ciprofloxacin 0.5–1 0.5 1
Ofloxacin 1–8 4 8
Pefloxacin 4–32 8 16
Penicillin 0.03–0.06 0.06 0.06
Amoxicillin ,0.015–0.5 0.06 0.06
Vancomycin 0.5–1 0.5 1
Teicoplanin ,0.06–0.25 0.25 0.25
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ever, were 16- and 32-fold higher, respectively, than the MIC90
of trovafloxacin. This is in agreement with recent reports (6,
11). The MICs for 204 clearly defined species within the viri-
dans group streptococci are shown in Table 2. We found higher
rates of penicillin resistance among S. mitis isolates than
among isolates of other species of viridans group streptococci.
This has previously been reported by others (3, 8). Trovafloxa-
cin inhibited 90% of the b-hemolytic streptococci at concen-
trations of #0.25 mg/liter, 2-, 4-, and 32-fold less than the
MIC90 of sparfloxacin, ciprofloxacin, and ofloxacin, respec-
tively.
Depending on the species tested, trovafloxacin was two- to
eightfold more active than sparfloxacin and 4- to 64-, 8- to 32-,
and 16- to 256-fold more active than ciprofloxacin, ofloxacin,
and pefloxacin, respectively.
The emergence of high rates of penicillin resistance in viri-
dans group streptococci has recently been reported in Europe
and in the United States (4, 8, 17). In our study, 1.5% of the
viridans group streptococci were highly resistant to penicillin
(MICs, $4 mg/liter). For 17.5% of the strains the MICs of
penicillin were 0.125 to 2 mg/liter (i.e., intermediate resis-
tance). Ninety percent of the penicillin-susceptible (MICs,
#0.06 mg/liter) viridans group streptococci were inhibited by
trovafloxacin concentrations of #0.25 mg/liter. The MIC90 of
trovafloxacin for the intermediately resistant and highly resis-
tant viridans group streptococci were #0.25 mg/liter and there-
fore identical to the MIC90 for the penicillin-susceptible
strains. The MICs of trovafloxacin for the four viridans group
streptococci that were highly resistant to penicillin (MICs, 4 to
16 mg/liter) were 0.06 to 0.25 mg/liter.
The recent emergence of penicillin resistance may have im-
plications for the therapy as well as the prophylaxis of infec-
tions with viridans group streptococci, e.g., endocarditis and
bacteremia (8, 18). In this respect, the increased activity of
trovafloxacin against penicillin-susceptible as well as penicillin-
resistant viridans group streptococci is promising. Clinical ex-
perience in the treatment of endocarditis with fluoroquino-
lones, however, is limited to the use of ciprofloxacin and
rifampin in patients with right-sided staphylococcal endocardi-
tis (10, 19). These studies report high success rates for combi-
nation therapy that includes ciprofloxacin. However, the emer-
gence of resistance to ciprofloxacin and rifampin during the
treatment of right-sided S. aureus endocarditis has been de-
scribed (14, 26). Treatment regimens involving oral adminis-
tration of quinolones have been used for treatment of experi-
mental enterococcal endocarditis with variable success (24, 28,
30). Also in an experimental setting, sparfloxacin was found to
be an effective drug for the treatment of endocarditis due to
penicillin-susceptible as well as penicillin-resistant viridans
group streptococci (12). These reports, together with the pre-
TABLE 2. In vitro activities of trovafloxacin (CP-99,219) and other
agents against 204 well-defined viridans group streptococcal species
from patients with endocarditis and those with
other bloodstream infections
Microorganism
(no. of strains) Antibiotic
MIC (mg/liter)
Range 50% 90%
S. oralis (62) Trovafloxacin 0.015–0.5 0.125 0.25
Sparfloxacin 0.125–2 0.5 2
Ciprofloxacin 0.5–32 4 16
Ofloxacin 0.5–16 4 4
Pefloxacin 4–128 32 64
Penicillin 0.008–8 0.03 0.25
Amoxicillin 0.008–2 0.03 0.25
Vancomycin 0.06–2 0.5 1
Teicoplanin 0.03–4 0.25 0.25
S. mitis (56) Trovafloxacin 0.03–4 0.125 0.5
Sparfloxacin 0.125–32 0.5 2
Ciprofloxacin 1–64 2 8
Ofloxacin 1–32 2 16
Pefloxacin 0.25–128 16 32
Penicillin ,0.015–4 0.06 1
Amoxicillin ,0.015–8 0.06 0.5
Vancomycin 0.5–8 1 2
Teicoplanin 0.015–16 0.125 0.25
“S. milleri” (25) Trovafloxacin ,0.008–0.5 0.125 0.5
Sparfloxacin 0.25–2 0.5 1
Ciprofloxacin 0.5–16 2 8
Ofloxacin 1–16 2 4
Pefloxacin 0.5–32 8 16
Penicillin 0.008–1 0.06 0.06
Amoxicillin 0.008–1 0.125 0.25
Vancomycin 0.5–2 1 2
Teicoplanin 0.03–0.25 0.125 0.25
S. gordonii (23) Trovafloxacin 0.03–1 0.125 0.25
Sparfloxacin 0.03–0.5 0.25 0.5
Ciprofloxacin 0.5–4 2 4
Ofloxacin 0.25–4 2 2
Pefloxacin 4–64 16 32
Penicillin ,0.015–16 ,0.015 0.5
Amoxicillin ,0.015–.16 0.06 0.5
Vancomycin 0.5–2 1 1
Teicoplanin 0.06–8 0.25 2
S. bovis (20) Trovafloxacin 0.125–0.5 0.25 0.25
Sparfloxacin 0.125–2 0.5 2
Ciprofloxacin 2–4 2 4
Ofloxacin 4 4 4
Pefloxacin 16–64 32 64
Penicillin 0.03–2 0.06 0.06
Amoxicillin 0.06–8 0.06 0.25
Vancomycin 0.5–1 0.5 0.5
Teicoplanin 0.125–1 0.25 0.5
S. mutans (18) Trovafloxacin ,0.008–0.5 0.125 0.25
Sparfloxacin 0.125–16 0.5 2
Ciprofloxacin 1–4 2 4
Ofloxacin ,0.008–4 2 4
Pefloxacin 8–128 32 32
Penicillin ,0.015–0.25 0.03 0.06
Amoxicillin ,0.015–0.25 0.03 0.125
Vancomycin 0.5–2 1 2
Teicoplanin ,0.015–2 0.125 1
TABLE 3. In vitro activities of trovafloxacin (CP-99,219) and
ciprofloxacin against VRE, MRSA, ciprofloxacin-resistant
MSSA, and ciprofloxacin-resistant CoNS isolated
from sources other than blood
Microorganism
(no. of strains) Antibiotic
MIC (mg/liter)
Range 50% 90%
VRE (20) Trovafloxacin 0.125–2 0.5 1
Ciprofloxacin 0.5–16 2 4
MRSA (13) Trovafloxacin 0.008–1 0.25 1
Ciprofloxacin 0.125–64 4 16
MSSA (13) Trovafloxacin 0.06–1 0.5 1
Ciprofloxacin 4–32 16 32
CoNS (19) Trovafloxacin 0.5–8 0.5 4
Ciprofloxacin 2–64 16 64
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sented data, suggest the importance of further experimental
and clinical evaluation of the efficacy of trovafloxacin in the
treatment of bacterial endocarditis and other infections caused
by gram-positive microorganisms.
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